With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Safe on first.
CRISPR-edited autologous T-cell infusions have proven for the first time in the US to be feasible and safe in three humans with refractory heme malignancies and sarcoma, though it remains to be seen if it was safe for the cancers too. | Stadtmauer, ASH 2019